甲状腺癌透明细胞变:临床病理与分子研究及多种遗传异常识别
研究回顾1992至2012年20例患者21个具有透明细胞特征的甲状腺原发癌(占0.5%),其中12例(57%)为滤泡癌,5例为经典型乳头状癌,2例为乳头状癌滤泡亚型,2例为低分化癌。分子检测15例发现RAS突变5例(33%)、PAX8-PPARgamma易位2例、EML4-ALK易位1例、TFG-MET易位1例。结论认为透明细胞变罕见,更常见于滤泡癌,常与RAS突变相关,应按同级别同分期癌处理。
要点
- 甲状腺癌透明细胞变罕见,占本机构甲状腺癌0.5%。
- 透明细胞变更常见于滤泡癌(12/21,57%),而非乳头状癌。
- 透明细胞变常与RAS突变相关(5/15,33%)。
核心结论
- 甲状腺癌透明细胞变罕见,更常见于滤泡癌而非乳头状癌,常与RAS突变相关,应按同级别同分期癌处理。
研究设计与样本
- 研究于1992至2012年识别20例患者共21个具有透明细胞特征的甲状腺原发癌,占本机构甲状腺癌0.5%。
- 对其中15例成功进行SNaPshot多基因突变分析和易位检测。
主要发现
- 12例(57%)为滤泡癌,5例为经典型乳头状癌,2例为乳头状癌滤泡亚型,2例为低分化甲状腺癌。
- 5例有RAS突变(4例滤泡癌和1例乳头状癌),2例有PAX8-PPARgamma易位(均为滤泡癌,其中1例伴p53突变)。
- 1例有EML4-ALK易位(乳头状癌),1例有TFG-MET易位(乳头状癌滤泡亚型)。
- 5例转移至区域淋巴结(3例滤泡癌和2例乳头状癌),2例转移至骨(均为滤泡癌)。
- 疾病局限于甲状腺者67%,区域淋巴结转移率24%,远处转移率10%,接近全国平均值(分别为68%、25%和5%)。
临床怎么用
- 作者认为甲状腺肿瘤出现透明细胞变应想到滤泡癌的可能,且不应按不同于同级别同分期其他癌的方式处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clear-cell carcinoma of the thyroid has been regarded as a variant of follicular (FTC) or papillary (PTC) thyroid carcinoma. Twenty-one primary thyroid carcinomas with clear-cell features, diagnosed in 20 patients (12 female) were identified between 1992 and 2012 (0.5% of in-house thyroid carcinomas). METHODS: Hematoxylin and eosin slides were reviewed. SNaPshot multigene mutational analysis and a translocation panel were successfully performed on 15 of these cases. RESULTS: Twelve (57%) were FTC, five were conventional PTC, two were follicular variant of PTC, and two were poorly differentiated thyroid carcinomas. Five cases had RAS mutation (four FTC and one PTC); two had PAX8-PPARgamma translocations (both FTC, one with concurrent p53 mutation); one had an EML4-ALK translocation (PTC); and one had a TFG-MET translocation (follicular variant of PTC). Five carcinomas were metastatic to regional lymph nodes (three FTC and two PTC), and two were metastatic to bone (both FTC). Disease confined to the thyroid (67%) and rates of regional lymph node metastasis (24%) and distant metastasis (10%) were near the national averages (68%, 25%, and 5%, respectively). One patient with a poorly differentiated thyroid carcinoma died one year after diagnosis, and a patient with metastatic FTC died two years after diagnosis. Overall mortality was 10%. CONCLUSIONS: Clear-cell change in thyroid carcinoma is rare, is more common in FTC than it is in PTC, is found focally or multifocally within a given lesion, and is frequently associated with RAS mutations (33%). Clear-cell change in thyroid neoplasia should raise the possibility of follicular carcinoma, and should not be treated differently from other carcinomas of similar grade and stage.
引用
- Cipriani NA, Agarwal S, Dias-Santagata D, et al. Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies. Thyroid. 2017. PMID: 28293986. doi:10.1089/thy.2016.0631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。